Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from The use of anti-IL-5 in eosinophilic gastrointestinal disorders (EGIDs); a systematic review. Local targets link to admitted publications; unresolved targets remain external evidence.
Eosinophilic gastrointestinal disorders (EGID)
10.1016/j.jaci.2003.10.047 · 2004 · External reference
Eosinophilic gastrointestinal disorders
10.1007/s12016-019-08732-1 · 2019 · External reference
Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis
10.1136/gutjnl-2023-329873 · 2023 · External reference
Advances in clinical management of eosinophilic esophagitis
10.1053/j.gastro.2014.07.055 · 2014 · External reference
Older patients with eosinophilic esophagitis have high treatment response to topical steroids
10.1016/j.dld.2021.10.004 · 2022 · External reference
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial
10.1016/j.jaci.2011.11.044 · 2012 · External reference
Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody
10.2165/11584340-000000000-00000 · 2011 · External reference
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
10.1056/nejmoa070812 · 2008 · External reference
Eosinophilic esophagitis in the era of biologics
10.1080/17474124.2024.2374471 · 2024 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Unresolved reference
2026 · External reference
An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis
10.1053/j.gastro.2011.07.044 · 2011 · External reference
Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease
10.1016/j.jaip.2022.02.037 · 2022 · External reference
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
10.1136/gut.2009.178558 · 2010 · External reference
Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial
10.1136/gutjnl-2023-330337 · 2023 · External reference
Safety and efficacy of Reslizumab for children and adolescents with Eosinophilic esophagitis treated for 9 years
10.1097/mpg.0000000000001840 · 2018 · External reference
Eosinophilic esophagitis
10.1016/j.mcna.2018.08.009 · 2019 · External reference
Prevalence of Eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017
10.1016/j.cgh.2017.05.050 · 2017 · External reference
Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy
10.1038/ajg.2014.166 · 2014 · External reference
Food allergy and eosinophilic esophagitis
10.1097/aci.0b013e328338cbab · 2010 · External reference
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome
10.1016/j.jaci.2014.07.026 · 2014 · External reference
Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases
10.1016/j.gtc.2014.02.007 · 2014 · External reference
Eosinophilic gastrointestinal disorders pathology
2018 · External reference
Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference
10.1053/j.gastro.2018.07.009 · 2018 · External reference
Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation
10.1016/j.molcel.2015.01.026 · 2015 · External reference
The eosinophil
10.1146/annurev.immunol.24.021605.090720 · 2006 · External reference
Oesophageal intrasquamous IgG4 deposits: an adjunctive marker to distinguish eosinophilic oesophagitis from reflux oesophagitis
10.1111/his.12892 · 2016 · External reference
CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference
2018 · External reference
Eosinophilic gastrointestinal disorders pathology
2017 · External reference
Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets
10.3389/fphys.2021.815842 · 2022 · External reference
Efficacy of dupilumab in a phase 2 randomized trial of adults with active Eosinophilic esophagitis
10.1053/j.gastro.2019.09.042 · 2020 · External reference
